The clinical progress is positive but expected; cash runway remains tight despite the recent $10M offering. Watch for enrollment completion and top-line data in early 2027, which are the primary catalysts. The increased loss rate keeps dilution risk alive.
Price Chart
Executive Summary
Annovis Bio reported Q1 2026 results showing increased net loss per share ($0.63 vs $0.32) and cash burn, but highlighted strong enrollment progress in its pivotal Phase 3 Alzheimer's trial (85% enrolled) and Parkinson's open-label extension study (40% enrolled), along with a positive DSMB recommendation. The clinical milestones support the NDA timeline but financial deterioration is a concern.
Key Financial Metrics
Key Facts
- Phase 3 AD trial enrollment at 85%; full enrollment on track for summer 2026
- PD OLE study enrollment at 40%; full enrollment expected Q4 2026
- Positive DSMB recommendation for buntanetap safety at 6 months
- Net loss per share widened to $0.63 from $0.32 in Q1 2025
- Cash and equivalents $14.2M as of March 31, 2026, plus $10M April direct offering
- NDA submission for symptomatic AD treatment expected early 2027
Financial Impact
Net loss increased to $17.6M from $5.5M year-over-year; cash burn accelerated due to Phase 3 trial costs
Risk Factors
- Clinical trial failure or data miss could devastate stock
- Cash burn may require additional dilutive financing before data readout
- Regulatory path for NDA uncertain until Phase 3 results
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-062451 |
| Document: tm2614822d1_8k.htm | 0001104659-26-062451 |
| Document: 0001104659-26-062451-index-headers.html | 0001104659-26-062451 |
| Document: 0001104659-26-062451-index.html | 0001104659-26-062451 |
| Document: 0001104659-26-062451.txt | 0001104659-26-062451 |
| 8-K Data (Synthetic) | 0001104659-26-062451 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 10, 2026 12w ago | 8-K | $1.86 $1.88 | ▲ +1.08% | ▼ −1.35% | $1.18 (−36.56%) |
May 20, 2026 19w ago | 424B5 | $2.15 $1.73 | ▲ +19.53% | ▲ +19.87% | $1.18 (+45.12%) |
May 19, 2026 19w ago | 424B5 | $2.04 $1.75 | ▲ +14.22% | ▲ +14.96% | $1.18 (+42.16%) |
May 15, 2026 20w ago | 8-K | $2.05 $1.79 | ▼ −12.68% | ▼ −14.26% | $1.18 (−42.44%) |
May 15, 2026 20w ago | Press Release | $2.06 $1.78 | ▲ +13.59% | ▲ +15.71% | $1.18 (+42.72%) |
Apr 10, 2026 25w ago | Press Release | $1.59 $2.26 | ▲ +42.14% | ▲ +33.61% | $1.18 (−25.79%) |
Mar 19, 2026 28w ago | Press Release | $2.67 $1.87 | ▼ −29.96% | ▼ −37.58% | $1.18 (−55.81%) |
Mar 16, 2026 28w ago | Press Release | $2.83 $1.73 | ▼ −38.87% | ▼ −42.65% | $1.18 (−58.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access